The Asia Pacific Biosimulation Market is expected to witness market growth of 17.8% CAGR during the forecast period (2024-2031).
The China market dominated the Asia Pacific Biosimulation Market by country in 2023, and is expected to continue to be a dominant market till 2031; thereby, achieving a market value of $697.5 million by 2031. The Japan market is registering a CAGR of 17.1% during 2024-2031. Additionally, the India market is expected to showcase a CAGR of 18.5% during 2024-2031.
Technological advancements in cloud computing and high-performance computing have further democratized access to these tools. Cloud-based platforms allow researchers and organizations to perform complex simulations without significant infrastructure investments. This accessibility has benefited small and mid-sized biotech firms, which can now compete with larger players in developing innovative therapies.
The growing focus on biologics and biosimilars has significantly increased the demand for these technologies. Biologics, such as monoclonal antibodies, cell therapies, and vaccines, rely on complex biological systems, requiring advanced tools to model their interactions effectively. They accelerates their development by predicting how these therapies interact with targets in the body, enabling researchers to refine designs before clinical trials.
Australia’s market is uniquely positioned, benefiting from its world-class clinical trial ecosystem and government-backed programs like the Medical Research Future Fund (MRFF). Moreover, the growing prevalence of chronic diseases presents a significant public health challenge, with over 15.4 million individuals living with at least one chronic condition, as reported by the Australian Institute of Health and Welfare (AIHW). This widespread burden underscores the importance of biosimulation technologies in addressing the nation’s healthcare needs. Thus, the region will present lucrative growth opportunities to expand the market.
The China market dominated the Asia Pacific Biosimulation Market by country in 2023, and is expected to continue to be a dominant market till 2031; thereby, achieving a market value of $697.5 million by 2031. The Japan market is registering a CAGR of 17.1% during 2024-2031. Additionally, the India market is expected to showcase a CAGR of 18.5% during 2024-2031.
Technological advancements in cloud computing and high-performance computing have further democratized access to these tools. Cloud-based platforms allow researchers and organizations to perform complex simulations without significant infrastructure investments. This accessibility has benefited small and mid-sized biotech firms, which can now compete with larger players in developing innovative therapies.
The growing focus on biologics and biosimilars has significantly increased the demand for these technologies. Biologics, such as monoclonal antibodies, cell therapies, and vaccines, rely on complex biological systems, requiring advanced tools to model their interactions effectively. They accelerates their development by predicting how these therapies interact with targets in the body, enabling researchers to refine designs before clinical trials.
Australia’s market is uniquely positioned, benefiting from its world-class clinical trial ecosystem and government-backed programs like the Medical Research Future Fund (MRFF). Moreover, the growing prevalence of chronic diseases presents a significant public health challenge, with over 15.4 million individuals living with at least one chronic condition, as reported by the Australian Institute of Health and Welfare (AIHW). This widespread burden underscores the importance of biosimulation technologies in addressing the nation’s healthcare needs. Thus, the region will present lucrative growth opportunities to expand the market.
List of Key Companies Profiled
- Certara, Inc.
- Dassault Systemes SE
- Advanced Chemistry Development, Inc.
- Genedata AG (Danaher Corporation)
- Instem Group of Companies
- Chemical Computing Group ULC
- Simulations Plus, Inc.
- Schrodinger, Inc.
- PPD, Inc. (Thermo Fisher Scientific, Inc.)
- Physiomics Plc
Market Report Segmentation
By Product- Software
- Molecular Modeling & Simulation Software
- Clinical Trial Design Software
- PK/PD Modeling and Simulation Software
- Pbpk Modeling and Simulation Software
- Toxicity Prediction Software
- Other Software Type
- Services
- Contract Services
- Consulting
- Other Services Type
- License-based Model
- Subscription-based Model
- Service-based Model
- Pay Per Use Model
- Life Sciences Companies
- Academic Research Institutions
- Other End Use
- Drug Discovery & Development
- Disease Modeling
- Other Application
- Cloud-based
- On-premises
- Hybrid Model
- Oncology
- Cardiovascular Disease
- Infectious Disease
- Neurological Disorders
- Other Therapeutic Area
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Competition Analysis - Global
Chapter 5. Asia Pacific Biosimulation Market by Product
Chapter 6. Asia Pacific Biosimulation Market by Pricing Model
Chapter 7. Asia Pacific Biosimulation Market by End Use
Chapter 8. Asia Pacific Biosimulation Market by Application
Chapter 9. Asia Pacific Biosimulation Market by Deployment Model
Chapter 10. Asia Pacific Biosimulation Market by Therapeutic Area
Chapter 11. Asia Pacific Biosimulation Market by Country
Chapter 12. Company Profiles
Companies Mentioned
- Certara, Inc.
- Dassault Systemes SE
- Advanced Chemistry Development, Inc.
- Genedata AG (Danaher Corporation)
- Instem Group of Companies
- Chemical Computing Group ULC
- Simulations Plus, Inc.
- Schrodinger, Inc.
- PPD, Inc. (Thermo Fisher Scientific, Inc.)
- Physiomics Plc
Methodology
LOADING...
